Trustmark National Bank Trust Department acquired a new stake in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,995 shares of the medical research company’s stock, valued at approximately $225,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 160 shares during the last quarter. Meeder Asset Management Inc. boosted its position in PRA Health Sciences by 144.0% during the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 906 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in PRA Health Sciences by 232.3% during the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock valued at $121,000 after purchasing an additional 1,289 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in PRA Health Sciences during the first quarter valued at $136,000. Finally, CAPROCK Group Inc. acquired a new stake in PRA Health Sciences during the second quarter valued at $208,000. 98.37% of the stock is owned by hedge funds and other institutional investors.

PRAH has been the subject of a number of research reports. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. Jefferies Group LLC reissued a “buy” rating and set a $92.00 price objective (up previously from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Citigroup Inc. reissued a “buy” rating and set a $93.00 price objective (up previously from $90.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Bank of America Corporation initiated coverage on PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 price objective for the company. Finally, Credit Suisse Group lifted their price objective on PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. PRA Health Sciences presently has an average rating of “Buy” and a consensus price target of $84.22.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/2995-shares-in-pra-health-sciences-inc-prah-purchased-by-trustmark-national-bank-trust-department/1578175.html.

PRA Health Sciences, Inc. (PRAH) traded down 0.07% during trading on Thursday, reaching $75.58. The company’s stock had a trading volume of 36,569 shares. PRA Health Sciences, Inc. has a 52 week low of $50.87 and a 52 week high of $80.99. The company has a market cap of $4.74 billion, a P/E ratio of 48.79 and a beta of 0.45. The company’s 50 day moving average price is $75.71 and its 200 day moving average price is $70.59.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the Zacks’ consensus estimate of $0.72 by ($0.10). PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The business had revenue of $457.90 million for the quarter, compared to analyst estimates of $447.79 million. During the same quarter in the prior year, the company earned $0.63 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. On average, equities analysts anticipate that PRA Health Sciences, Inc. will post $3.19 earnings per share for the current fiscal year.

In related news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $711,075,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Linda Baddour sold 100,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $7,485,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,000,000 shares of company stock valued at $748,500,000. Company insiders own 2.10% of the company’s stock.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.